Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs FPA 150 (Primary)
  • Indications Advanced breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Five Prime Therapeutics
  • Most Recent Events

    • 16 Oct 2018 According to the Five Prime Therapeutics media release, company Initiates Patient Dosing in The Dose Exploration Cohort of Its Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150
    • 28 Mar 2018 According to a Five Prime Therapeutics media release, dosing of patients have been started.
    • 28 Mar 2018 Status changed from planning to recruiting, according to a Five Prime Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top